Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	2	19,852	N/A	N/A	69.81% (12.27% to 89.61%)
Severe or critical COVID‐19 after complete vaccination	2	19,852	N/A	N/A	N/A
All‐cause mortality	1	12,396	Risk Ratio (M‐H, Random, 95% CI)	0.50 (0.05 to 5.52)	N/A
Serious adverse events	4	23,139	Risk Ratio (M‐H, Random, 95% CI)	0.97 (0.62 to 1.51)	N/A
Systemic reactogenicity events	6	23,956	Risk Ratio (M‐H, Random, 95% CI)	0.95 (0.55 to 1.62)	N/A
Any adverse event	6	23,367	Risk Ratio (M‐H, Random, 95% CI)	1.09 (1.07 to 1.11)	N/A
Local reactogenicity events	6	23,962	Risk Ratio (M‐H, Random, 95% CI)	1.76 (1.69 to 1.82)	N/A